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in the United Kingdom since 2008. Moreover, many pa-
tients in the United Kingdom with NDM-1-producing 
Gram-negative bacilli had traveled to India or Pakistan 
within the same year.2 Similar infections have been ob-
served in the United States, Candida, Australia and the 
Netherlands,3,4 suggesting a possibility of global spread.
The NDM-1 carbapenemase poses little genetic identity 
to other metallo-β-lactamases, but shares 32.4% of identity 
with VIM-1/VIM-2. NDM-1 can hydrolyze all β-lactams 
except aztreonam,1 but universal resistance to aztreonam 
in clinical NDM-1-producing isolates suggested that the 
possibility of concurrent presence of additional β-lactamses, 
which had been identified as AmpC and extended-spectrum 
β-lactamases (ESBLs) enzymes.2 These findings are not 
surprising because recent studies demonstrated the prev-
alence rate of ESBLs in Enterobacteriacae reaches 70–90% 
in India.5 Moreover, the NDM-1-producing pathogen is 
highly resistant to other antibiotics, such as fluoroqui-
nolones and aminoglycosides, which were clinically used 
for Gram-negative infections.2 A good news is that these 
isolates remain susceptible to tigecycline (56–67%) or col-
istin (89–100%).2 However, low concentration of tigecycline 
in serum with presently recommended dosages precluded 
its use for bacteremia, and colistin therapy was often hesi-
tated due to its nephrotoxicity in critically ill patients. So 
far, there is no susceptibility information of fosfomycin 
for NDM-1-producing pathogens, but a worrisome fact 
is that fosfomycin susceptibility is lower in ESBL- or 
metallo-β-lactamase- producing Enterobacteriacae than those 
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A new type of carbapenemase, New Delhi metallo-β-
lactamase (NDM)-1, has been recently identified in 
Enterobacteriacae isolates. Multidrug resistant NDM-1 
pathogens spread quickly and caused human infections 
in the community and hospitals in many countries. This 
finding has attracted worldwide attentions.1 The blaNDM-1 
gene encodes an enzyme, which confers resistance to car-
bapenems and other β-lactams. The blaNDM-1 gene harbors 
in Enterobacteriacae, mainly Klebsiella pneumoniae and 
Escherichia coli, which can cause community-onset or 
healthcare-associated infections. The first case of NDM-1 
infection was found in a Swedish patient of India origin, 
who has been admitted to a hospital in New Delhi.1 
Besides, Kumarasamy et al demonstrated the outbreak of 
NDM-1-producing bacteria in India, Pakistan and United 
Kingdom.2 They found that blaNDM-1 gene was detected in 
1–13% of carbapenem-resistant Enterobacteriacae strains 
in India, and NDM-1-producing isolates predominated 
in 44% of the carbapenemase-producing Enterobacteriacae 
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isolates without indicated β-lactamases.6 Nevertheless, it 
is predictable that the clinically available drugs for infec-
tions caused by NDM-1-producing pathogen will be very 
limited, and currently few antibiotics with significant 
antibacterial activity against Gram-negative bacteria are 
under development in pharmaceutical industry.7
A recent study highlighted that NDM-1-producing 
strains had a ready access of transferring its resistant 
genes to other Enterobacteriacae species through transcon-
jugation.1,2 A molecular epidemiological survey revealed 
that some isolates with NDM-1 in India were clonally re-
lated while the others were clonally diverse.2 Therefore, it 
is highly possible that NDM-1-producing pathogens can 
be globally spread. To make it worse, the global explosion 
of CTX-M-type ESBL in Enterobacteriacae makes the thera-
peutic choice shifting towards carbapenems. The selective 
pressure for the emergence of carbapenemase-producers 
would grow up consequently. The typical scenario for the 
former was the emergence of a novel carbapenemase, 
K. pneumoniae carbapenemase (KPC), which spread world-
wide and caused hospital-associated infections in many 
countries.8–10 Although KPC and NDM-1 β-lactamases 
share a similar phenotype of carbapenems resistance, NDM-
1-producing strains,11 but not KPC-producing strains,12 
could be recognized by the current screening methods of 
MBL production, such as modified Hodge test, imipenem-
EDTA double-disc synergy tests, or metallo--lactamase 
E-test (AB bioMerieux, Solna, Sweden).1 Comparisons of 
epidemiological and microbiological characters of KPC 
and NDM-1-producing bacteria are summarized in the 
Table.
The variation of medical services and expenditure be-
tween countries would have an impact on the epidemiol-
ogy of infectious diseases. For example, it is not uncommon 
Table. Summary of microbiological and epidemiological features of two carbapenemases, NDM-1 and KPC
Characteristics NDM-1 KPC
Year of identification 2009 2001
Endemic areas India, Pakistan & United Kingdom Worldwide
Clone spread Yes (some are diverse clones) Yes
Source of infection Community and hospital Hospital
Bacteria species Mainly K. pneumoniae or E. coli;  Predominately K. pneumoniae 
 Enterobacter spp., Citrobacter
 freundii, Morganella morganii, 
 Providencia spp.
Horizontal transmission to other species Possible Rare
Drug resistancea Highly resistant Highly resistant
Carbapenem resistance High High
Susceptibility to candidate antibiotics
 Colistin Susceptible Susceptible
 Tigecycline Intermediate Resistant
 Gentamicin Resistant Susceptible
 Fosfomycin Unknown Intermediate
Screening test MBL production positive (Modified  MBL production negative; 
 Hodge test, imipenem-EDTA imipenem-boronic acid disk
 synergistic test, MBL E-test) synergy test positive
Confirmation test PCR detection of blaNDM-1 gene PCR detection of blaKPC gene
Infection control in hospitals Contact isolation Contact isolation
aStrains with NDM-1 or KPC are resistant to nearly all β-lactams. NDM = New Delhi metallo-β-lactamase; KPC = Klebsiella pneumoniae 
carbapenemase; MBL = metallo-β-lactamase; EDTA = ethylenediaminetetraacetic acid; PCR = polymerase chain reaction.
 353
A continuous challenge from Gram-negative bacteria
for people to access medical care in different countries for 
economic reason. The so-called “medical tourism” would 
facilitate the spread of multidrug-resistant bacteria between 
continents. It is evident that many patients with infections 
due to NDM-1-producing bacteria had received surgeries in 
India.4 Therefore, some experts advocate that it merits regu-
lar screening of multidrug-resistant pathogens, especially for 
those with a history of medical care in endemic countries.4
Physicians worldwide are facing the growing challenge 
of carbapenem-resistant Gram-negative bacteria. Clinicians 
should be alert of the possibility of NDM-1-producing 
Enterobacteriacae infection in patients ever having medical 
care in endemic areas. Optimal antimicrobial therapy war-
rants further in vitro and clinical studies. Patients with in-
fection or colonization due to NDM-1-producing pathogens 
in the hospital should be placed in contact isolation.13 As 
for routine practices in microbiological laboratories, car-
bapenem resistance and carbapenemase production con-
ferred by blaNDM-1 can be detected by phenotypic methods 
as recommended by the Clinical and Laboratory Standards 
Institute.14 Strains obtained from patients receiving medical 
care in endemic areas, and with carbapenem resistance and 
metallo--lactamase production, should be submitted for 
NDM-1 screening. Moreover, the emergence of multidrug-
resistant bacteria highlights the needs for international 
collaboration with a worldwide, multicenter surveillance 
for the emergence of those superbugs.
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